A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naive Metastatic Castration-Resistant Prostate Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
January 17, 2019
End Date
December 16, 2024
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
January 17, 2019
End Date
December 16, 2024